P24011-01 Pre-Assessment

Medical Learning Institute Inc

Home
About Us
Accreditation
- About MLI Accreditation
- Joint Providership Request
Activities
- Upcoming Events
- On-Demand Activities
Educational Series
- Featured Educational Series
A Quick Dose of CE
Contact Us

Home
About Us
Accreditation
- About MLI Accreditation
- Joint Providership Request
Activities
- Upcoming Events
- On-Demand Activities
Educational Series
- Featured Educational Series
A Quick Dose of CE
Contact Us

Medical Learning Institute Inc

Home
About Us
Accreditation
- About MLI Accreditation
- Joint Providership Request
Activities
- Upcoming Events
- On-Demand Activities
Educational Series
- Featured Educational Series
A Quick Dose of CE
Contact Us

Name *

First

Last

Email *

Organization/Institution *

Address *

Address Line 1

Address Line 2

City

State / Province / Region

Postal Code

Country

Please provide your unique provider identifier (ex. NPI in US, BIG in Netherlands, etc).

Please provide your License number and State (if applicable)

1. A 45-year-old with AML underwent allo-HCT and is on immunotherapy to prevent GVHD. Blood tests and imaging suggested PTLD and biopsy confirmed EBV+ PTLD. The potential burden of EBV+ PTLD in this patient is… *

a. ↑ morbidity and ↓ mortality with complex management
b. ↓ morbidity and ↑ mortality with complex management
c. ↓ morbidity and ↓ mortality with complex management
d. ↑ morbidity and ↑ mortality with complex management
e. Unsure/I Don’t Know

2. Which statement describes the current prognosis scoring systems for EBV+PTLD? *

a. They incorporate genetic and molecular profiling but may not account for patient response to rituximab
b. They rely heavily on clinical features such as age and comorbidities but may not account for immune status and type of transplant
c. They predict long-term survival for all patients, regardless of their initial response to treatment and the timing of PTLD onset
d. They are consistently updated to include new research findings and therapeutic interventions
e. Unsure/I Don’t Know

3. A 55-year-old patient underwent an auto-HCT for MM. After diagnosis of EBV+ PTLD you consider reducing immunosuppressive therapy and administering rituximab to target the EBV-infected B-cells, reduce lymph node size, and provide symptomatic relief. According to the NCCN guidelines for EBV+ PTLD, and for this patient, rituximab should be… *

a. First-line treatment, regardless of the patient's immune status and EBV viral load
b. Combined with chemotherapy as the first-line treatment
c. Part of the initial treatment, particularly in patients with high EBV viral load and evidence of B-cell proliferation
d. Used after other therapies have failed to show efficacy
e. Unsure/I Don’t Know

4. In the ALLELE trial, what was the estimated 1-year OS among patients who responded to tabelecleucel compared to non-responders (1-year OS 34.8%)? *

a. 38.2%
b. 52.3%
c. 69.6%
d. 84.4%
e. Unsure/I Don’t Know

5. A 60-year-old patient with CLL underwent an allo-HCT. She presents with persistent fever, night sweats, and unintentional weight loss. Upon diagnosis of EBV+ PTLD, you discuss tabelecleucel, a novel EBV-specific T-cell therapy, along with a reduction in immunosuppressive therapy. Based on the ALLELE trial, what are the most common grade ≥3 TEAEs you will discuss? *

a. Disease progression and diarrhea
b. Decreased neutrophil count and constipation
c. Disease progression and decreased neutrophil count
d. Decreased appetite and abdominal pain
e. Unsure/I Don’t Know

6. How confident are you in your ability to treat and manage patients with EBV+ PTLD? *

a. Not at all confident
b. Somewhat confident
c. Confident
d. Highly confident

Medical Learning Institute Inc
40946 US Highway 19N, #602
Tarpon Springs, FL, 34689
888.654.2631 (toll-free)
609.333.1693 (direct)

Scroll to Top